Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over. NICE technology appraisal guidance 1085
National Institute for Health and Care Excellence (NICE)
Record ID 32018014406
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta1085
Year Published:
2025
URL for published report:
https://www.nice.org.uk/guidance/ta1085
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Cystic Fibrosis
- Cystic Fibrosis Transmembrane Conductance Regulator
- Drug Combinations
- Aminophenols
- Chloride Channel Agonists
- Indoles
- Pyrazoles
- Pyridines
- Pyrrolidines
- Quinolones
- Child
- Adolescent
- Adult
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.